Guangdong Pharmaceutical University Licenses 100,000-Yuan Botanical Anti-Inflammatory Cream Patent to Zhongshan Aihoo Daily Chemicals, Filling a Gap in Low-Irritation Infant Skincare

Recently, Guangdong Pharmaceutical University released a public notice on patent transfer, proposing to transfer the university’sLiu Huanyu's TeamR&DInvention Patent for an Anti-inflammatory Cream for Infants and Toddlers and Its Preparation Method, intended to¥100,000Transferred at price to Zhongshan Aihu Daily Necessities Co., Ltd.

Image from the official website of Guangdong Pharmaceutical University

This transaction involves the market-oriented commercialization of university research achievements by a daily chemical enterprise, with the core beingImplementing Low-Irritation Anti-Inflammatory Cream Technology Adapted for Infant and Toddler Skin. This patent addresses the pain point of infants' and toddlers' delicate skin, which is prone to irritation-induced redness, swelling, and inflammation, by eliminating the high-irritation drawbacks associated with traditional medications, usingNatural Plant Compound ExtractFeaturing core anti-inflammatory ingredients combined with a gentle skincare base, it forms a safe, hypoallergenic, and highly effective anti-inflammatory formulation system. By integrating dual technological innovations in gentle skincare and anti-inflammatory repair, it fills the market gap for mild anti-inflammatory skincare products specifically designed for infants and young children.

Skin inflammation is essentially a defensive inflammatory response triggered by bacterial invasion of the human skin.Common pathogenic bacteria primarily include Staphylococcus aureus, Group A Streptococcus, Pseudomonas aeruginosa, and Vibrio parahaemolyticus. Invasion by these pathogens leads to typical local symptoms of “redness, swelling, heat, and pain,” along with functional impairment. In severe cases, bacteria and their toxins may enter the bloodstream, potentially inducing toxemia or sepsis, which can be life-threatening.

Compared with adults, infants and young children have particularly delicate and fragile skin due to the immaturity of their skin barrier function. Influenced by multiple stimuli from external environmental factors (such as temperature fluctuations and humidity levels), physical friction (from clothing materials), and contact with the environment, infant skin is highly susceptible to damage, leading to pathological conditions such as desquamation, erythema, and inflammation. Such inflammation not only causes physical distress but also severely impacts the growth, development, and quality of life of infants and young children.

However, current conventional clinical interventions for skin inflammation are mainly divided intoSystemic Medication and Topical TherapyTwo categories: this regimen holds certain clinical value in managing general skin inflammation and can alleviate symptoms. However, when the aforementioned conventional treatment protocols are applied to the infant and toddler population,Significant limitations and safety concerns exist:

First, most existing medications are designed for adults and can be highly irritating to the delicate skin of infants and young children. Second, certain drug components (such as antibiotics and potent antihistamines) pose higher metabolic risks in infants and young children, carrying significant potential for toxic side effects. Finally, many clinically used drugs are not suited to the physiological characteristics of infants and young children, and may even disrupt their immature immune systems or cutaneous microecology.

Due to the insufficient safety and compatibility of existing treatment options, there has long been a product gap in the field of infant and toddler skin inflammation care. There is an urgent clinical and market need to develop aLow irritation, low toxicity and side effects, eco-friendly, healthy, safe, and gentlededicated anti-inflammatory productsProduct. Such products must effectively resolve pathological issues in infants and young children, such as skin redness, swelling, and inflammation, while fully ensuring medication safety and skin health.

This technology breaks through the traditional treatment of infant and toddler skin inflammation"Balancing Efficacy and Safety Is Challenging"bottlenecks, with its core advantages and innovations mainly reflected inFormulation, Safety, and Manufacturing ProcessThree Dimensions.Formula InnovationGuided by the theories of Traditional Chinese Medicine (TCM) and employing a natural combination approach, we have constructed a multi-target anti-inflammatory system that overturns the traditional paradigm of relying on single chemical compounds for inflammation control. We scientifically formulated extracts from multiple natural herbs, including menthol, aloe vera, lithospermum, licorice, chamomile, purslane, and zedoary turmeric. By leveraging the synergistic effects of these ingredients in reducing inflammation, alleviating pain, and promoting blood circulation to remove stasis, this formulation addresses the limited efficacy associated with single-component anti-inflammatory agents. Furthermore, as all active ingredients are derived from natural plants and free from harsh synthetic chemicals, the product ensures a green, gentle, and inherently natural profile from its source.

Safety InnovationFocusing onInfant-Specific Low-Irritation Formula, creating a dual safety barrier by combining anti-inflammatory ingredients with high-quality, skin-friendly bases such as jojoba oil, simmondsia chinensis (jojoba) oil, and white petrolatum. These bases not only provide moisturizing and reparative benefits but also form a protective layer on the skin to reduce direct irritation from active ingredients. The product has been rigorously validated through the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) assay, yielding an average score of less than 1, with no hemorrhage or vascular lysis observed. This evidence-based data substantiates its low-irritancy and high-safety profile, fully meeting the usage standards for delicate infant and toddler skin.

Process Innovationrelies onPrecision Temperature Control and Homogeneous Microemulsion Preparation Technology, a three-phase stepwise preparation method is employed, utilizing Phase A as the oil phase, Phase B as the aqueous phase, and Phase C as the functional phase. The temperature nodes are strictly controlled, with heating at 80–90°C and cooling at 70–75°C for each phase, to ensure the fineness and stability of the cream. Meanwhile, anti-inflammatory plant extracts are added during the low-temperature stage at 60–65°C to prevent thermal degradation of heat-sensitive active ingredients, thereby maximizing the retention of the product’s biological activity and anti-inflammatory efficacy.

In summary, this technology, throughNatural Plant Blends, Skin-Friendly Matrix Repair, Precision Manufacturingthree-dimensional innovation, successfully creating a baby-specific cream that combines high-efficiency anti-inflammatory properties (with a maximum swelling inhibition rate of 101%) and extreme gentleness, effectively filling the market gap for safe and effective anti-inflammatory care products.

Currently, the baby skincare cream market is in a high-quality development phase driven by safety and compliance. Industry regulation follows“Safety First, Minimalist Formula”Principles, the filing and testing systems are becoming increasingly robust. On the consumer side, parenting practices are growing more refined, with parents placing significantly greater emphasis on ingredient purity and efficacy suitability. Demand is shifting from basic moisturization to specialized functions such as sensitive skin repair and barrier strengthening. In terms of distribution channels, online-offline integration is deepening, with professional pharmacies, maternal-and-infant retail channels, and e-commerce platforms jointly building a distribution network that covers both daily care and special-use scenarios.

Looking ahead, the market will move towardDirections of Joint Medical Research and Development, Scientific Formulation of Ingredients, and Precise EfficacyEvolution. As parenting philosophies advance and regulatory standards become more stringent, products featuring a gentle and safe base, clear efficacy data, and clinical support will dominate the market. The industry’s growth is sustainable, with competition increasingly focusing on product strength and professional value, thereby driving the market landscape toward greater maturity and rationality.

Ji Chu Baby Anti-Dryness Soothing & Protective Cream (Little Green Jar) is a medically co-developed infant and toddler skincare product, created through a collaborative research partnership between Chando Group and the National Children’s Medical Center – Children’s Hospital of Fudan University.Designed for the dry, sensitive, and eczema-prone skin of infants and toddlers, this product focuses on barrier repair and maintaining skin stability, belonging to the category of professional infant and child skincare with a medical research background. Centered around the patented ingredient Fu'er Aibeijian, it is combined with moisturizing and soothing ingredients suitable for infant and toddler skin. The formula is gentle, complies with safety standards for children's cosmetics, and features a dense, moisturizing texture, making it suitable for long-term use during dry seasons and for fragile skin barriers.

In terms of market application, supported by clinical research and endorsed by professional institutions, this product has entered numerous professional channels, including Grade A tertiary hospitals, child healthcare centers, chain pharmacies, and high-end postpartum care centers. It also covers large national chain retail outlets and mainstream e-commerce platforms, promoting its widespread use in daily home care scenarios. Positioned as a long-term skincare solution for infants and children with sensitive skin and eczema-prone skin, the product is extensively used in pediatric clinical care, daily household moisturizing and repair, and maintenance care for sensitive skin. As a representative product of medically co-developed functional skincare for infants and children, it has established a stable foundation of application and industry recognition in the market for infant and child sensitive skin care.

Winona Baby Soothing and Nourishing Cream is a professional, efficacy-based skincare product under the Winona Baby brand, specifically designed for the sensitive and delicate skin of infants and children.Developed based on a dermatological-grade R&D system, the formula focuses on gentle soothing, moisturizing and repair, and barrier strengthening. It is enriched with botanical extracts such as Prinsepia utilis oil, Portulaca oleracea, and Calendula officinalis, combined with multiple moisturizing agents and ceramide-related components. The product aims to alleviate skin discomforts such as dryness and redness. Formulated in compliance with safety standards for children’s cosmetics, it features a pure and gentle composition, making it suitable for daily use on the delicate skin of infants and young children.

In terms of market application, supported by clinical studies and endorsed by professional institutions, this product is widely used in scenarios such as daily household moisturizing and soothing, long-term barrier maintenance for sensitive skin, and skincare for dryness and seasonal transitions. It has also gained popularity in professional settings, including adjunctive dermatological care in pediatrics and recommendations in child health education. The product is available through diverse channels, including mainstream e-commerce platforms, specialized maternal and infant stores, chain pharmacies, and offline supermarkets. With a stable user base and solid market presence in the repair of infant and toddler sensitive skin and the care of dry skin, it stands as one of the representative products in China’s functional skincare sector for infants and children.

The infant and toddler anti-inflammatory cream developed by this patented technology, with its"Natural plant extracts, low irritation, high safety"its core attributes precisely align with the prevailing trend in the current children’s skincare market toward specialization and efficacy-driven solutions. By leveraging scientifically formulated combinations of traditional Chinese herbal medicines and rigorous manufacturing processes, this technology achieves distinct anti-inflammatory and reparative effects while ensuring product gentleness, thereby effectively addressing consumers’ dual demands for ingredient purity and precise functionality in the context of refined parenting.

Supported by robust experimental data and a mature industrialization pathway, this technology lays a solid foundation for translation into scenarios of daily home care and clinical adjunctive therapy. It not only fills the market gap in the niche segment of gentle anti-inflammatory care for infants and toddlers but also aligns with the industry’s structural shift from basic moisturizing to co-creation between medical research and industry, as well as the precise enhancement of efficacy. Therefore, this patented technology holds significant differentiated competitive advantages in the pediatric functional skincare sector, demonstrating robust and sustainable commercialization potential and market promotion value.